GlassScriptPhysician profile
Jeffrey G Rogers
NPI 1588664312
$35,870.43
in general payments reported to CMS, 2019-2025
23 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $408 · 2021: $516 · 2022: $12K · 2023: $20K · 2024: $1,712 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $18K · Travel and Lodging: $1,854 · Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $18,178.46 |
| Travel and Lodging | $1,853.82 |
| Food and Beverage | $1,653.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29,337.16 | 2022-2024 | Nexplanon |
| Medical Device Business Services, INC. | $2,119.71 | 2021-2023 | Enseal |
| Boston Scientific Corporation | $2,094.34 | 2019-2025 | Obtryx System - Curved, Solyx Sis System |
| Coloplast Corp | $775.06 | 2019-2023 | Altis |
| Ethicon US, LLC | $487.54 | 2021-2025 | Enseal X1, Dermabond Prineo, Harmonic |
| Abbvie INC. | $391.41 | 2019-2023 | Orilissa |
| Hologic Sales and Service, LLC | $154.53 | 2021-2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Evofem Biosciences, INC. | $85.51 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $71.33 | 2023-2025 | |
| Daiichi Sankyo INC. | $53.17 | 2022-2023 | Injectafer |
| Femselect INC. | $46.78 | 2023 | Enplace |
| Biogen, INC. | $44.76 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $27.91 | 2021 | |
| Medtronic, INC. | $26.21 | 2022 | |
| Genmab U.S., INC. | $24.31 | 2023 | Tivdak |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.64 | 2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $19.90 | 2022 | |
| Roche Diagnostics Corporation | $19.21 | 2021 | |
| Amgen INC. | $16.54 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $14.75 | 2024 | Bd Onclarity |
| Teleflex LLC | $13.19 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.45 | 2021 | |
| Caldera Medical, INC | $11.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.